Recent developments from Anavex Life Sciences have captured significant attention in the medical community. The company’s investigational drug, blarcamesine (ANAVEX2-73), has demonstrated notable efficacy in reducing amyloid-ß biomarkers in patients with early Alzheimer’s disease.  The positive findings emerged from a phase 2b/3 trial that enrolled 508 participants, aiming to explore the cognitive and functional efficacy […]